|Mr. Dror Ben-Asher||Co-Founder, Chairman & CEO||555.97k||N/A||1966|
|Mr. Micha Ben-Chorin||Chief Financial Officer||418.05k||N/A||1969|
|Mr. Gilead Raday||Chief Operating Officer||388.25k||N/A||1975|
|Mr. Adi Frish||Chief Corp. & Bus. Devel. Officer||407.21k||N/A||1970|
|Mr. Rick D. Scruggs||Chief Commercial Officer, Head of US Operations & Director||577.99k||N/A||1960|
|Ms. Alexandra Okmian||Sr. Bus. Devel. & Investor Relations Mang.||N/A||N/A||N/A|
|Mr. Ben Martie||VP, Legal Affairs||N/A||N/A||N/A|
|Ms. Valerie Graceffa||VP of Sales||N/A||N/A||N/A|
|Mr. Rob Jackson||Sr. VP of Sales & Marketing||N/A||N/A||N/A|
|Ms. Michelle Snelling||VP of HR||N/A||N/A||N/A|
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focused on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 1/2a study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis, and has completed Phase 2 studies for irritable bowel syndrome with diarrhea; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and Phase 2a study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; and RHB-106, an encapsulated formulation for bowel preparation, which has completed Phase 2a study. The company was incorporated in 2009 and is headquartered in Tel Aviv, Israel.
RedHill Biopharma Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.